Sort
23,748 grants matching “melanoma”
PHASE II/III CLINICAL TRIALS OF ANTICANCER AGENTS
$496,374University Of Texas Md Anderson Can Ctr · U01 · FY2000 · CA
Therapeutic strategies for treatment of giant congenital melanocytic nevi
$496,338David E Fisher · Massachusetts General Hospital · R01 · FY2024 · AR
The Role of T Cell Avidity in Determining Tumor Immunity and Autoimmunity
$496,305Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Rare Cancer Genetics Registry
$496,059Dianne M Finkelstein · Massachusetts General Hospital · R01 · FY2012 · CA
Managing Incidental Findings and Research Results in Genomic Biobanks and Archive
$496,018Susan M Wolf · University Of Minnesota · R01 · FY2010 · HG
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
$495,996Iman Osman · New York University School Of Medicine · R01 · FY2021 · CA
A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously
$495,751Lawrence Kwong · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma
$495,652Ryan J Sullivan · Massachusetts General Hospital · R01 · FY2017 · CA
Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.
$495,600Emily H Cheng · Sloan-Kettering Inst Can Research · U54 · FY2023 · CA
Project 1- Bioadhesive Sunscreens and Triplet-State Quenchers for Melanoma Prevention
$495,427Michael Girardi · Yale University · P50 · FY2022 · CA
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells
$495,420Bin Zhang · Northwestern University At Chicago · R01 · FY2020 · CA
Melanoma RAS/BRAF Mutation--Heterogeneity-Risk-Prognosis
$495,393Nancy E Thomas · Univ Of North Carolina Chapel Hill · R01 · FY2008 · CA
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
$495,372Edgar G. Engleman · Stanford University · R01 · FY2025 · CA
Project 2: Understanding the Cellular Origins of Melanoma
$495,239Anand K Ganesan · University Of California-Irvine · U54 · FY2021 · CA
Leveraging cross-cancer shared heritability to better understand the genetic architecture of cancer
$494,993Sara Lindstroem · University Of Washington · U01 · FY2023 · CA
Risk Factors for Nevus Development in Children
$494,961Lori A Crane · University Of Colorado Denver · R01 · FY2014 · CA
Imaging Probe: Lymph Node Identification &Localization
$494,929Photon Imaging, Inc. · R44 · FY2001 · RR
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin
$494,928Konstantinos Votanopoulos · Wake Forest University Health Sciences · R01 · FY2022 · CA
Enhanced Viro-Immunotherapy for Breast Cancer Brain Metastasis
$494,886Ji Young Yoo · University Of Texas Hlth Sci Ctr Houston · R01 · FY2025 · CA
Therapeutically harnessing anti-viral resident memory T cells in solid tumors
$494,877Pamela Rosato · Dartmouth College · R01 · FY2025 · CA
A pooling project on alcohol use and risk of cancers with inconsistent prior evidence, with an emphasis in non-smokers.
$494,761Pietro Ferrari · International Agency For Res On Cancer · R01 · FY2017 · AA
NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma
$494,541Xiao-Fan Wang · Duke University · R01 · FY2023 · CA
Automatic Detection of Critical Dermoscopy Features for Melanoma Diagnosis
$494,442William V Stoecker · Stoecker & Associates · R44 · FY2007 · CA
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma
$494,436Devanand Sarkar · Virginia Commonwealth University · R01 · FY2022 · CA
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma
$494,436Devanand Sarkar · Virginia Commonwealth University · R01 · FY2023 · CA